08189 泰達生物
按盘价 
0.188 +0.018 (+10.588%) 盈利能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 资产回报率 (%) | -6.295% | -8.209% | -11.412% | -12.718% | -20.871% |
| 股东资金回报率 (%) | -33.582% | -32.893% | -34.661% | -28.736% | -36.472% |
| 资本运用回报率 (%) | -23.323% | -23.629% | -27.161% | -24.168% | -41.177% |
边际利润分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 毛利率 (%) | 5.368% | 3.646% | 9.573% | 10.936% | 9.755% |
| 未计利息、税项、折旧及摊销前利润率 (%) | 0.969% | -1.216% | -6.568% | -10.871% | -18.164% |
| 税前边际利润率 (%) | -3.018% | -5.892% | -9.412% | -13.537% | -24.757% |
| 纯利率 (%) | -5.065% | -6.250% | -8.870% | -12.995% | -23.588% |
变现能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 流动比率 (X) | 0.878 X | 0.885 X | 1.087 X | 1.339 X | 1.625 X |
| 速动比率 (X) | 0.461 X | 0.546 X | 0.695 X | 0.867 X | 1.056 X |
财务杠杆分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 总负债 / 总资产比率 (%) | 78.706% | 75.934% | 68.251% | 60.515% | 43.216% |
| 总债项 / 总资产比率 (%) | 27.551% | 30.429% | 25.991% | 13.909% | 10.339% |
| 净债项 / 总资产比率 (%) | 25.595% | 28.396% | 18.385% | 10.465% | 3.639% |
| 总债项 / 股东资金比率 (%) | 167.278% | 146.347% | 89.643% | 38.207% | 19.587% |
| 长期债项 / 股东资金比率 (%) | 40.630% | 50.254% | 44.862% | 30.383% | 0% |
| 净债项 / 股东资金比率 (%) | 155.397% | 136.568% | 63.409% | 28.747% | 6.895% |
| 净现金 / (债项) ($) | (7.76千万) | (9.57千万) | (6.39千万) | (4.11千万) | (1.32千万) |
| 每股净现金 / (债项) ($) | (0.041) | (0.051) | (0.034) | (0.022) | (0.007) |
| 总债项 / 资本运用比率 (%) | 96.670% | 86.262% | 58.072% | 27.517% | 18.208% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 存货周转率日数 (日) | 79.691日 | 62.855日 | 70.692日 | 100.178日 | 98.394日 |
| 应收贸易帐周转率日数 (日) | 18.637日 | 25.953日 | 29.105日 | 51.189日 | 69.391日 |
| 应付贸易帐周转率日数 (日) | 16.888日 | 20.396日 | 28.081日 | 31.154日 | 30.247日 |
| 备注： | 实时报价更新时间为04/10/2024 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | RMB -4,123,183 |
| 增长率 | -63.350% |
| 每股盈利/(亏损) | RMB -0.002 |
| 每股账面资产净值 (¥) | RMB 0.024 |